Clinical Trial Update: A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and tolerability of oral AZD3241 in patients with Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AZD3241

Snippet

Sponsor: AstraZeneca | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED